Slide 1: Interim report Q1 2011/12
Interim report Q1 2011/12 By CEO Lars Marcher and CFO Anders Arvai
Slide 2: Agenda
Agenda • Developments in Q1 2011/12 • Status of GPS Four • Outlook for 2011/12
Slide 3: Highlights in Q1 2011/12
Highlights in Q1 2011/12 • Expected flat development in revenue • Products launched after start of GPS Four strategy period 1 Oct. 2009 account for 10% of revenue • Intensified strengthening of sales resources in the US and Asian markets • Increased gross margin • Hedging of silver price reduces cas
Slide 4: Satisfactory EBIT and net profit
Satisfactory EBIT and net profit Revenue EBIT, DKKm Net profit for the period, DKKm • Revenue for Q1 2011/12 • Gross margin up at 56.7% • Net financials amounted to totalled DKK 234m against from 56.4% in the same income of DKK 1m against DKK 233m in Q1 2010/11, period last year expenses of DKK 2m l
Slide 5: Development – markets
Development – markets USA, DKKm Europe, DKKm Rest of the world, DKKm • Revenue growth of 2% • Fall in revenue of 1% • Combined growth in in local currencies and • Varying growth rates - revenue in the rest of the 3% in Danish kroner growth in sales regions world of 2% • Satisfactory growth NEM and C
Slide 6: Development – business areas
Development – business areas Anesthesia, DKKm Patient Monitoring Emergency Care, DKKm & Diagnostics, DKKm • Anesthesia: the former • Revenue growth of 1% • Fall in revenue of just over Airway Management in local currencies and 1% in local currencies and business area plus single- in Danish kroner in
Slide 7: Cash flow
Cash flow DKKm Q1 2010/11 Q1 2011/12 Cash flow from operating activities (3) (19) Cash flow from investing activities, incl. acquisitions (6) (9) Free cash flow (9) (28) Cash flow from financing activities 15 35 • Cash flow from operating activities reduced due to more funds being tied up in working
Slide 8: GPS Four – Status of Ambu’s business strategy
GPS Four Status of Ambu’s business strategy
Slide 9: GPS Four – overview
GPS Four — overview PLATFORM DEVELOPMENT 2009-2010 Establishment of sales regions Establishment of global innovation organisation Implementation of global IT systems Moving of remaining production in Denmark to Asia initiated Expansion of factory in China Ambu™ Idews thet work for © COST OPTIMISATIO
Slide 10: Update on activities relating to the GPS Four strategy
Update on activities relating to the GPS Four strategy • The products SmartInfuser™ Pain Pump and SmartBlock™ were launched in the US market at the end of Q1 2011/12. • Strengthening of sales organisation in the USA, including establishment of internal sales team with a view to increasing sales of A
Slide 11: Market situation
Market situation Market situation Ambu’s position and strategy • Favourable outlook and attractive • Ambu’s products contribute to enhanced growth opportunities efficiency, lower healthcare costs and • Variation from market to market – improved patient treatment strongest growth in emerging markets
Slide 12: Growth areas
Growth areas • Organic growth from the USA and EMEA, among other things driven by the earlier increase in the number of both external and internal salespeople in the USA and much more targeted sales efforts in EMEA. • New growth markets in Asia and Brazil. The markets are characterised by strong gro
Slide 13: Outlook 2011/12
Outlook 2011/12
Slide 14: Outlook for 2011/12
Outlook for 2011/12 2011/12 Comments Revenue In the region of DKK 1,025 - Increased revenue in emerging markets and 1,035m success with new products Growth When measured in DKK and local currencies Approx. 5% Increased market share Formation of partnerships USD exchange rate: 540 GBP exchange rate:
Slide 15: Questions
a \. q " - "| “. is >= . ‘ <*, 4 Ms, hs i 7 — SS <3 Ambu? ’. oe. R&S s that work for life AA & cs Questions
Slide 16: For further information, please contact
READ MORE AT WWW.AMBU.COM For further information, please contact: CEO Lars Marcher, lm@ambu.com or +45 5136 2490 CFO Anders Arvai, aa@ambu.com or +45 7225 2000